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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe discovery of induced pluripotent stem cells (iPSCs) and the concurrent development of protocols for their cell-type-specific differ-
entiation have revolutionized our approach to cell therapy. It has now become critical to address the challenges related to the generation
of iPSCs under current good manufacturing practice (cGMP) compliant conditions, including tissue sourcing, manufacturing, testing,
and storage. Furthermore, regarding the technical challenges, it is very important to keep the costs of manufacturing and testing reason-
able and solve logistic hurdles that permit the global distribution of these products. Here we describe our efforts to develop a process for
the manufacturing of iPSC master cell banks (MCBs) under cGMPs and announce the availability of such banks.INTRODUCTION
Induced pluripotent stem cell (iPSC)-based therapy is a
newly developing field and builds on several key technical
advances that have enabled the widespread use of embry-
onic stem cell (ESC)-based technology (Ellerstro¨m et al.,
2006; Rao 2008; Rao and Condic 2008; Chen et al., 2012)
for drug discovery and basic biology. Companies such as
Geron, Asteris, Ocata (formerly known as Advanced Cell
Technology), Biotime, Viacyte, and J&J have developed
products from ESCs, several have initiated early-stage clin-
ical trials (Carpenter and Rao, 2015), and several patients
have been treatedwith no deleterious side effects (Schwartz
et al., 2012). These results have led companies such as Hea-
lios and Megakaryon to initiate plans to generate products
using iPSCs. Recently, a study involving one patient treated
with retinal pigment epithelium (RPE) cells derived from
iPSCs was carried out using cells manufactured in a current
good laboratory practice (cGLP) environment using autol-
ogous cells (http://www.dddmag.com/articles/2014/10/
japan-starts-world-first-stem-cell-trial-plans-more).
These groups have demonstrated to the Food and Drug
Administration (FDA) that products derived from pluripo-
tent stem cells (PSCs) can be manufactured without a
demonstrable risk of contaminating undifferentiated cells.
Although current good manufacturing practice (cGMP)
compliant cells have been generated from ESCs (Crook
et al., 2007; Tannenbaum et al., 2012), most of the cells
were derived under non-cGMP conditions and then quali-
fied for cGMP by additional testing. The cells were exposedStem Cellto xenogeneic agents and feeder cells, and/or, in some
cases, donor consent would not permit their use as a com-
mercial product. To our knowledge, no fully cGMP-
compliant cell line has been generated where the entire
manufacturing process, from tissue sourcing to cell expan-
sion and banking processes as well as documentation, raw
materials, staff training, cell therapy facility, and quality
control (QC) testing, was validated.
Developing a cGMP-compliant manufacturing protocol
or using integration-free methods and xenogeneic-free ma-
terial in a cGMP-compliant facility will not be sufficient to
ensure clinically relevant products, nor will adding certifi-
cation or training complete the process. Conformation to
regulations governing the acquisition of human donor tis-
sue will need to be ensured (in the United States according
to FDA21CFR 1271HumanCells, Tissues, andCellular and
Tissue-based Products). Reference or control material will
need to be developed to generate convincing data on in-
process testing, lot-to-lot variability, and release assays.
The assays themselves will need to be developed and qual-
ified or validated (depending on the clinical trial phase of
application). Moreover, cGMP manufacturing require-
ments that are incompatible with cell manufacture need
to be modified, including developing specific guidance
for sterility/aseptic processes for patient-specific cells.
Attention will need to be paid to the different interpreta-
tions of ethical issues, patent law, and the special property
rights issues that arise for cells that may make gametes
(Andrews et al., 2014). In addition to being in compli-
ance with FDA regulations, one will need to comply withReports j Vol. 5 j 647–659 j October 13, 2015 j ª2015 The Authors 647
Figure 1. An Overview of the Manu-
facturing of Human Induced Pluripotent
Stem Cells under cGMPs
A tissue acquisition program was estab-
lished, focusing on defining tissue re-
quirements, working with a tissue recovery
agency, establishing forms and standard
operating procedures, recovering tissue,
and donor eligibility determination. The
manufacturing started with the isolation of
CD34+ cells from a fresh cord blood unit and
continued to priming, expansion, and then
reprogramming of CD34+ cells. After gener-
ation of iPSCs and expansion, the cells were
banked and eventually tested. Every step of
the manufacturing process was documented
and performed according to the batch re-
cords and standard procedures. Following
characterization of the final bank, the re-
sults were reviewed by the quality assurance
group to release the GMP iPSC lot.requirements that are imposed by institutional review
boards (IRBs), the Health Insurance Portability and Privacy
Act (HIPPA), and the Office for Human Research Protection
(OHRP). Furthermore, given that iPSC-derived cells may
be distributed internationally, the cell manufacturing pro-
cess will need to adhere to additional country-specific
guidelines as well. Developers will also have to devise a
strategy for international distribution in countries where
regulations are still being formulated (http://c.ymcdn.
com/sites/www.celltherapysociety.org/resource/resmgr/
2014AnnualMeeting/ISCT2014-AcademicProgram_Web.pdf).
Given that a global effort has been initiated to develop
donor banks of human leukocyte antigen (HLA)-matched
iPSC banks that will serve as an extensive library for select-
ing close to optimal matches for patients (Turner et al.,
2013; Fairchild 2015; Solomon et al., 2015), it is clear that
the need for a large number of cGMP-compliant lines ex-
ists, and paying attention to international regulations
and not just United States regulations will be critical.
As a custommanufacturing organization (CMO) offering
cGMPmanufacturing services around a variety of cell ther-
apy products, Lonza attempted to develop clinically
compliant processes to generate cGMP-compliant human
iPSC lines. In this manuscript, we report the development
of such human iPSC lines that primarily address United
States regulations. We show that sourcing from cord blood
when using an optimized and reproducible integration-free648 Stem Cell Reports j Vol. 5 j 647–659 j October 13, 2015 j ª2015 The Amethod allows one to develop a bank of well characterized
and tested pluripotent cells that can be used for differenti-
ation into clinically relevant cells, holding potential for
clinical applications.RESULTS
Tissue Acquisition
Tissue for the derivation of cellular products must be ob-
tained by following the appropriate guidelines. Figure 1
illustrates some of themain activities associated with sourc-
ingdonor tissue foruse incell therapymanufacturing.These
activities include defining tissue requirements, working
with a tissue recovery agency, establishing forms and stan-
dard operating procedures, recovering tissue, and donor
eligibility determination. For this iPSC MCB, the starting
material was an umbilical cord blood unit. Critical elements
of the process included informed consent, which covered
the intended use of the donated tissue; the benefits, if any,
to the donor or others; the risks and potential discomfort
of the donation; confidentiality of donor information; and
a statement demonstrating voluntary participation of the
donor in the program, obtained from the mother. Notably,
the informed consent form developed for this study was re-
viewed and approved by the hospital IRB in which the cord
blood tissue collection work took place.uthors
Figure 2. Key Steps of the Human iPSC
Manufacturing Process
The manufacturing of human iPSCs under
defined and cGMP conditions include tis-
sue acquisition to obtain a fresh cord
blood unit, CD34+ cells isolation from the
cord blood, reprogramming of CD34+ cells
into iPSCs using the 4D nucleofector
system and episomal-based technology,
and expansion and banking of iPSCs. The
photomicrographs represent CD34+ cells
isolated from cord blood and expanded in
culture (CD34+ Isolation and Priming),
iPSC colonies on day 10 post-nucleofection (P0 Colonies), and iPSCs at passage 6 (P6 Colonies) passage 12 (P12 Culture). Scale
bars, 500 mm, except in the CD34+ Isolation and Priming image (250 mm).Another critical part of the donor tissue sourcing process
was donor eligibility determination, which was based on
the results of donor screening and testing. This activity
involved review of the medical records and a physical
exam.Additionally, clinical laboratory testingwasperformed
to test for relevant communicable disease agents or diseases
(RCDADs). The RCDADs listed in the regulations are HIV,
hepatitis B virus (HBV), hepatitis C virus (HCV), transmis-
sible spongiform encephalopathies (TSEs), human T-lym-
photropic virus (HTLV), Treponema pallidum, Chlamydia
trachomatis, and Neisseria gonorrhoea (see FDA 21 CFR 1271
regulations at http://www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/
Tissue/ucm073964.htm). Also, other communicable dis-
eases are considered relevant but not listed, such as West
Nile virus, sepsis, and Vaccinia virus.
The collection of cord blood tissue was performed ac-
cording to defined procedures by trained tissue recovery
specialists in a hospital setting using aseptic techniques
in accordance with good tissue practices (GTP) regulations
as stated in 21 CFR 1271. The tissue was packaged and
shipped to the manufacturing site (Lonza Walkersville) us-
ing validated procedures (American Association of Blood
Banks [AABB]- and Foundation for the Accreditation of
Cellular Therapy [FACT]-accredited). When received, the
tissue was stored appropriately and transferred to an as-
signed cell therapy area according to standard protocols.
In the interim, the quality assurance (QA) group reviewed
the initial documents, which included the date of tissue
collection, shipping and handling conditions, and tissue
volume/size. When approved, the tissue entered the
manufacturing process. Because the process utilized a fresh
cord blood unit, the initial cell isolation and priming steps
were performed under quarantine conditions until the re-
sults of the screening and testing were received. When
the data were received, they were reviewed by a qualified
person (Lonza’s medical director) and the QA group. After
sign-off, the tissue was released from quarantine status.Stem CellDevelopment of a cGMP-Compatible Process
iPSC MCBs have to be generated using a robust, reproduc-
ible, and cGMP-compliant manufacturing process,
applying best practices for cell culture, documentation,
and quality control (Stacey et al., 2013). Our early iPSC gen-
eration studies focused on the development of a reliable
and efficient process that resulted in a sufficient number
of high-quality iPSC clones and could be successfully tran-
sitioned into the GMP manufacturing suites. The reprog-
ramming process was evaluated based on the number of
generated iPSC colonies, morphology and quality of iPSC
colonies, and expression of pluripotency markers using
flow cytometry and immunostaining. A defined and
feeder-free cell reprogramming and cell culture system
was developed to avoid the issues of lot-to-lot variability,
regulatory and safety concerns of co-culture, and scalability
challenges. Important parameters evaluated and optimized
in the process development phase included the reprogram-
ming method, nucleofection parameters, reprogramming
enhancers, cell culture medium, matrix and subculture re-
agents, expansion and subculture protocols, and character-
ization of human iPSCs. Figure 2 illustrates the critical
manufacturing steps of cord blood (CB)-derived CD34+
cells.
CB-derived CD34+ cells were chosen as the startingmate-
rial because of several practical and technical consider-
ations, as described previously (Rao et al., 2012). Selecting
CD34+ cells also eliminated the risk of reprogramming T
or B cells. During the process development phase, cryopre-
served vials of magnetic bead-isolated CD34+ cells were
used. This isolation process resulted in a population of
80% or more CD34+ cells. The cryopreserved CD34+ cells
were then thawed andprimed for a period of 4 days in ame-
dium supporting the expansion of CD34+ cells. The quality
of the cells, level of expansion, and purity of CD34+ cells
were evaluated based on the morphology; cell counts on
days 0, 1 (after splitting the cells), and 4 (prior to nucleofec-
tion); and flow cytometry analysis on days 0 and 4. OnReports j Vol. 5 j 647–659 j October 13, 2015 j ª2015 The Authors 649
average, the priming step yielded a 4- to 8-fold expansion
of CD34+ cells and allowed the evaluation of multiple re-
programming conditions.
Given the safety concerns surrounding the use of inte-
grating viral vectors (Okita et al., 2011; Goh et al., 2013),
a non-integrative episomal-based technology initially
developed by Chou et al. (2011) was used for reprogram-
ming based on a single transfection of two plasmids: pEB-
C5 and pEB-Tg (Chou et al., 2011). CD34+ cells were
transfectedwith the two plasmids using a cGMP-compliant
electroporation system. Because all of the commercially
available substrates we tested did not meet our success
criteria, we developed a proprietary matrix in-house (L7
human pluripotent stem cell [hPSC] matrix, unpublished
data). This matrix, in combination with a feeder-free cell
culture medium (Lonza L7 hPSC Medium, see Supple-
mental Experimental Procedures for additional informa-
tion), optimally supported the expansion of human plurip-
otent stem cells (unpublished data) and allowed us to
develop a feeder-independent system for the generation
of human iPSCs. However, we observed a significantly
lower reprogramming efficiency compared with reprog-
ramming using a feeder system. Therefore, further modifi-
cations were incorporated in the reprogramming process,
including the use of hypoxic culture conditions (3%–5%
O2) and a transforming growth factor b (TGF-b) inhibitor
(A83-01), a selective inhibitor of the TGF-b type I receptor
ALK5, which has been shown to enhance reprogramming
efficiency (Ichida et al., 2009). We also incorporated Alhy-
drogel (i.e., an aluminum hydroxide wet gel suspension),
which enhanced integration-free reprogramming under
defined and feeder-free conditions (Figure S1). The mecha-
nism of action of aluminum hydroxide is still under inves-
tigation, although it may act by the recently described
‘‘transflammation mechanism,’’ similar to Poly I:C, which
functions through cell surface Toll-like receptors (TLRs) to
promote reprogramming (Lee et al., 2012). Finally, a chem-
ically defined, non-enzymatic passaging solution (i.e.,
Lonza L7 hPSC Passaging Solution) based on sodium citrate
was used for serial subculture of iPSCs (Nie et al., 2014).
Combining these improvements in a complete system
allowed us to generate iPSCs reliably and reproducibly, as
assessed by testing (Figure S2).
Raw Material Handling and Supply Chain
Considerations for cGMP Manufacturing
An important component of establishing a cGMP
manufacturing process includes establishing a complete
list of raw materials as well as establishing relevant quality
control and bioassay tests, primary and secondary vendor
qualifications, rawmaterial part setup, and inventoryman-
agement (including storage conditions, tracking expira-
tion, reorder points, and material flow to and within650 Stem Cell Reports j Vol. 5 j 647–659 j October 13, 2015 j ª2015 The AGMPmanufacturing suites) (Stacey et al., 2013). Following
establishment of the process, a bill of material (BOM) was
created to evaluate the criticality of the materials for the
process and assess vendors’ qualifications based on the
United States regulatory requirements. In our case, vendor
evaluation was performed by supply chain and quality
assurance, focusing on accepted or approved vendors de-
pending on the criticality of the materials. Approved ven-
dors were evaluated using a written vendor questionnaire
along with verification of specific tests shown on the certif-
icate of analysis (COA) (see Supplemental Experimental
Procedures for evaluation of vendors for reprogramming
plasmids). Accepted vendors involved with QC test re-
agents or general supplies were evaluated based on obtain-
ing generic information around the materials with appro-
priate COAs as well as relevant material shipment
documents. Another important aspect of supply chain ac-
tivities was setting up client/project-specific part numbers
in the Enterprise Resource Planning (ERP) system. As part
of setting up each material in the system applications
and products (SAPs), all relevant information, including
the COA, material origin information, and shipping condi-
tions, were collected and included on the raw material
specification sheet (RMSS). The RMSS was then reviewed
and approved by the subject matter expert and QA group.
A specific part number was assigned to each rawmaterial at
the end of the part setup process. SAP was used throughout
the period of manufacturing process to facilitate the
handling, ordering, tracking, and availability of the mate-
rials from suppliers to the warehouse and from the ware-
house to the cGMP suite.
Transferring the Manufacturing Process to the
cGMP Suite
Following the optimization of human iPSC generation and
completing the process development phase, but prior to
manufacturing in a cGMP manufacturing suite, training
runs and engineering runs were performed. The purpose
of training runs is training of cell therapy technicians on
the process prior to execution of the actual process in a
manufacturing suite as well as development of draft
master batch records (MBRs). The training runs were car-
ried out in a process development/research laboratory.
Engineering runs, commonly referred to as validation
runs, served as the final evaluation of all prerequisites
related to manufacturing of iPSCs utilizing approved (or
near-approved) production records and standard operating
procedures (SOPs). The objective of the engineering runs
was to identify gaps throughout the entire manufacturing
process. Engineering runs were carried out in the cGMP
manufacturing suite, with products (including intermedi-
ate products and final products) being tested and evaluated
using cGMP testing protocols.uthors
It should be noted that training, engineering, and
cGMP manufacturing runs were all conducted using the
same optimized iPSC manufacturing process established
during process development (PD) runs, but they differ in
the process used for CD34+ cells isolation as described
below.
Phase I: Training Runs
Two training runs were initiated 20 days apart to generate
iPSC lines from cryopreserved research and development
(R&D)-grade, CB-derived CD34+ cells (derived from two
different donors) using the defined and cGMP-compatible
process and cell culture system established during the pro-
cess optimization phase. Two reprogramming methods
were used on each sample: episomal plasmids plus TGF-b
inhibitor (method A) and episomal plasmids plus TGF-b in-
hibitor and 2% Alhydrogel (method B). On days 10–12
post-nucleofection, six hiPSC colonies were isolated for
each method and donor for further expansion and charac-
terization. The remaining cell culture plate was stained
with alkaline phosphatase (AP). In training run 1, AP stain-
ing exhibited 110 potential iPSC colonies formethod A and
182 colonies for method B. In training run 2, 54 iPSC col-
onies were generated using method A and 39 colonies us-
ingmethod B. Following serial sub-culturing of the isolated
human iPSCs for four to six passages, all iPSC colonies were
cryopreserved. Two iPSC clones per donor were then
thawed after initial evaluation based on the quality of
each clone with respect to morphology, growth, and level
of spontaneous differentiation and serially sub-cultured
before banking and characterization. As illustrated in Fig-
ure S3, the iPSC clones (LiPSC-TR1.1) generated during
training run 1 proliferated and expanded under cGMP-
compatible conditions, stained positively for pluripotent
stem cell markers (OCT4, NANOG, TRA-1-60, TRA-1-81,
and SSEA4), exhibited potential to differentiate into all
three germ layers (ectoderm, endoderm, and mesoderm),
matched the genetic identity of starting material using
short tandem repeat (STR) analysis, and had a normal kar-
yotype at passage 16. Surprisingly, karyotype analysis of
both the CD34+ cells used as starting material for reprog-
ramming and iPSCs generated during training run 2
demonstrated an abnormal female karyotype with para-
centric inversion on the long arm of chromosome 7 in all
20 cells. We concluded that the karyotypic abnormality
was already present in the donor cells rather than intro-
duced during the reprogramming process. At the end of
the training runs, the draft MBRs as well as quality control
and testing documents, including the sampling plan, were
updated.
Phase II: Engineering Runs
For the engineering runs, we elected to use CD34+ cells
freshly isolated from CB for manufacturing cGMP iPSCs.
Because cryopreserved CD34+ cells had been used for PDStem Cellruns and training runs, we performed a gap analysis to re-
evaluate the CD34+ cell isolation step. The gap analysis
focused on pretreatment of the cord blood tissue prior to
cell separation using Miltenyi Biotec’s CliniMACS system,
improving the purity and yield of CD34+ cells, and
CD34+ cell format (cryopreserved versus fresh unfrozen
cells). Based on this gap analysis study, a proprietary
multi-step CD34+ cell isolation process was established.
Using the CliniMACS system in the CD34+ cell isolation
process, we achieved a purity of >60% CD34+ cells and a
yield of about 40% CD34+ isolation, with a minimum of
2.5 3 106 CD34+ cells required to start the priming step.
A total of two engineering runs were performed using
two R&D-grade tissues undergoing CD34+ cell isolation,
followed by a 4-day priming step. Following the reprogram-
ming ofmethods A and B as described earlier, nine iPSC col-
onies were isolated permethod and donor. The selected hu-
man iPSC colonies were subcultured until passages 5–7 and
cryopreserved. Each of the iPSC clones was evaluated based
on cell morphology and plasmid clearance. The plasmid
clearance assay was developed based on a qPCR assay (re-
sidual qPCR) to quantitatively detect residual EBNA/OriP
sequences originating from both pEB-C5 and pEB-Tg (see
Supplemental Experimental Procedures). Based on the re-
sults of the in-process controls, two to three clones per
donor were thawed, expanded further, and banked. We
found that the two clones generated during engineering
run 1 and expanded further to passage 19 were not clear
of the plasmids, which could indicate integration of
plasmid DNA. In contrast, three iPSC clones (clones A, B,
and G) generated during engineering run 2 exhibited an
undetermined level of cycle threshold (Ct) value using
qPCR assay at passages 10–13, confirming clearance. All
three iPSC clones demonstrated (1) the ability to recover
after cryopreservation, (2) expression of pluripotent stem
cell markers, (3) pluripotency using embryoid body (EB)
formation, (4) a genetic identity matching the starting
material, and (5) normal karyotype following banking (Fig-
ure 3 shows the characterization results for LiPSC-ER2.2).
The iPSCs generated during engineering run 2 also passed
standard safety assays for sterility, mycoplasma, and endo-
toxin tests. Based on the results of the engineering runs, the
MBRs were updated to include the CD34+ cell isolation
process and in-process controls.
Phase III: Manufacturing Runs
After completing the tissue acquisition and recovery proce-
dures described earlier, a fresh cord blood unit was sourced
from one donor, packaged, and shipped to the
manufacturing site according to the validated procedures.
When received, the cGMP-compliant tissue was quaran-
tined while initial documents associated with the tissue,
including the tissue collection date (i.e., August 14,
2014), shipping and handling conditions (roomReports j Vol. 5 j 647–659 j October 13, 2015 j ª2015 The Authors 651
Figure 3. Generation, Expansion, and Characterization of Human iPSCs: Engineering Runs—LiPSC-ER2.2
(A) Priming of CD34+ cells isolated from cord blood unit and expanded in culture on day 4 prior to nucleofection (Priming), the iPSC colony
emerged on day 4 post nucleofection (D4 Post-Nucleofection), iPSC colonies on day 11 post nucleofection (P0 colonies), iPSCs at passage 3
(P3 colonies), and iPSCs at passage 14 (P14 culture). Scale bars, 500 mm, except in the Priming image (250 mm).
(B) iPSCs stained positively with OCT4, TRA-1-60, SSEA4, NANOG, TRA-1-81, and AP. Scale bars, 250 mm, except in the AP image (500 mm).
(C) iPSCs expressing the pluripotent stem cell surface markers SSEA4, TRA-1-60, and TRA-1-81 (dark blue). Light blue indicates the isotype
control.
(D) iPSCs differentiated into embryoid bodies and readily expressing the markers for early ectoderm (TUJ1), endoderm (AFP), and
mesoderm (SMA). Scale bars, 125 mm.
(E) The iPSCs demonstrated a normal karyotype after 14 passages.
(F) STR analysis showed that the iPSCs matched the starting CD34+ donor sample.temperature), and tissue volume/size (total weight of 188 g
and a net cord blood volume of 156ml) were reviewed. The
manufacturing process was initiated within 36 hr of tissue
recovery. The CD34+ cell isolation process resulted in the
isolation of 1.74 3 107 total viable cells, 89.10% of which
were CD34+ cells passing the acceptance criteria for the
initial CD34+ cell isolation. Priming of the cells for 4 days
resulted in a more than 3-fold expansion and increase in
CD34+ cell purity (94.9% CD34+ cells) (Figure 4A). Karyo-652 Stem Cell Reports j Vol. 5 j 647–659 j October 13, 2015 j ª2015 The Atype analysis of the sample taken on day 4 demonstrated
that the enriched CD34+ cells were karyotypically normal.
The sterility test result was negative, confirming that the
CD34+ cell isolation and priming steps were carried out
in compliance with appropriate aseptic techniques. The
cells were then transfected with the pEB-C5 and pEB-Tg
plasmids using two nucleofection methods (one million
enriched CD34+ cells per method). After 18 days in the
L7 cell culture system, method A, which included TGF-buthors
Figure 4. cGMP Manufacturing of Human iPSCs: GMP Runs—LiPSC-GR1.1
(A) CD34+ cells isolated from afresh cord blood unit expanded and further purified from days 0–4 in the priming step. Black represents the
CD34+ cell population, and gray represents the isotype control.
(B) An iPSC colony on day 10 post-nucleofection (D10 P0 Colonies), iPSCs at passage 3 (P3 Colonies), and iPSCs at passage 13 (P13
Culture). Scale bars, 500 mm.
(C) iPSCs stained positively with OCT4, TRA-1-60, SSEA4, NANOG, TRA-1-81, and AP. Scale bars, 250 mm, except in the AP image (500 mm).
(D) iPSCs expressing the pluripotent stem cell surface markers SSEA4, TRA-1-60, and TRA-1-81 (dark blue). Light blue indicates the isotype
control.
(E) A dendrogram developed through whole gene expression analysis, confirming the clustering of the iPSC lines generated in this work and
lines published previously. The colored lines indicate iPSC clones generated from the same donor. F and M indicate iPSC generation from
female and male donors, respectively.
(F) The iPSCs demonstrated a normal karyotype after 14 passages in culture.
(G) STR analysis showed that the iPSCs matched the starting CD34+ donor sample.inhibitor only, resulted in the generation of nine hESC-like
colonies, three of which (clones A, D, and I) survived and
actively proliferated in culture after the colony isolation
step. Notably, the number of colonies observed for both re-
programming procedures during GMP run 1 was signifi-
cantly lower than the number of colonies observed during
PD runs, training runs, and engineering runs. Donor-to-
donor variability likely explains the low number of col-Stem Cellonies observed for method A (nine potential hiPSC col-
onies) and no colony observed for method B (Mack et al.,
2011). Despite this observation, we continued with the
manufacturing process according to established GMP
protocols and batch records, given the high quality of sur-
viving iPSCs (Figure 4B) and successful completion of
in-process testing (including sterility and karyotype).
Clone A (product no. CTI-1134, lot no. 50-001-02A) wasReports j Vol. 5 j 647–659 j October 13, 2015 j ª2015 The Authors 653
cryopreserved at passage 5, and clone D (product no. CTI-
1134, lot no. 50-001-02D) and clone I (product no. CTI-
1134, lot no. 50-001-02I) were cryopreserved at passage 6.
In-process residual plasmid clearance showed that all three
iPSC clones had undetermined levels of plasmid at the
cryopreservation point. In parallel to manufacturing,
screening and testing of the donor cells was performed by
an independent laboratory registered with the FDA. The
test results showed that the donor met the eligibility
criteria. The donor tested negative for HIV-1, HIV-2, hepa-
titis B, HCV, HTLV, cytomegalovirus (CMV), syphilis, and
West Nile virus. Upon confirmation of donor eligibility,
the starting tissue was released from quarantine status.
Following the confirmation of donor eligibility and in-
process evaluation of the cryopreserved intermediate
iPSC clones, two iPSC clones, lot no. 50-001-02A (here-
after labeled LiPSC-GR1.1) and lot no. 50-001-02D (here-
after labeled LiPSC-GR1.2), were selected, thawed, serially
subcultured, and finally banked. Each bank received a
unique part number for identification and was tested for
plasmid clearance one passage after thawing. Evaluation
of the lots was conducted at each passage until plasmid
clearance was confirmed for two consecutive passages
(LiPSC-GR1.1 at passages 7 and 8 and LiPSC-GR1.2 at pas-
sages 8 and 9). After confirming plasmid clearance, the
human iPSCs were expanded further. LiPSC-GR1.1 and
LiPSC-GR1.2 were cryopreserved at passage levels P14
and P13, respectively. For each line, between 150–200
vials (2 3 106 cells/vial) were cryopreserved. Although a
well-mixed cell suspension was used during the filling
process, each cryovial was labeled with a number indi-
cating the order of filling. Following the cryopreservation,
cryovials from the start, middle, and end of the filling pro-
cess were used for QC testing to ensure that the relatively
long filling process did not adversely affect the quality of
the cells.
QC Testing and Release Assays
In addition to developing a process to generate iPSCs, it was
critical to establish appropriate final product release testing
to ensure the identity, safety, purity, and viability of the
final products (Table S1). In the absence of specific guide-
lines for characterization of iPSCs, the decision was made
to include an assay as a release assay or for information
only (FIO) based on the criticality of the assay (i.e., indi-
cating safety, identity, or purity).
Upon evaluation of pluripotent stem cells using stan-
dard/qualified assays and other test methods, the human
iPSCs manufactured under cGMP conditions fulfilled the
main characteristics of pluripotent stem cells (Figures 4B–
4D) and passed standard safety assays, including the
plasmid clearance, karyotype (Figure 4F), STR (Figure 4G),
sterility, mycoplasma, and endotoxin tests.654 Stem Cell Reports j Vol. 5 j 647–659 j October 13, 2015 j ª2015 The AGene Expression Profiling of iPSC Lines
Whole genome expression analysis was performed on iPSC
lines generated during process development, training runs,
engineering runs, and GMP manufacturing runs (GEO:
GSE72078). Hierarchical clustering of all lines and overall
correlation co-efficiency (R2 value) between each line are
shown in Figure 4E and Table S2. The correlation co-effi-
ciency between each line manufactured in this study is
greater than 0.9. We further compared the gene expression
profile of these lines with several iPSC lines generated and
characterized previously (Pei et al., 2015; Shaltouki et al.,
2015) and found them to be closely correlated with the
R2 values of more than 0.9 for all lines crossed and
compared (Table S2). No significant difference in gene
expression profiles at a global level was observed among
the lines generated in this work and lines generated previ-
ously using similar or different reprogramming methodol-
ogies (Shaltouki et al., 2015).
In addition to the overall gene expression comparison,
we developed a panel of approximately 250 markers,
including markers of pluripotency, gender, imprint, endo-
derm, mesoderm, and ectoderm that can serve as quality
control for cells to be used and analyzed their expression
in these lines (data not shown). As expected, several plurip-
otency markers, including Oct4, Nanog, and Sox2, were
highly expressed in all iPSC samples. No difference was
observed between the male or female lines, and no change
in the expression of imprinted genes was seen. Overall, our
gene expression profiling of each line was similar and
similar to previously reported iPSC and ESC lines
(Momcilovic et al., 2014).
Validation of Neural Differentiation and Gene
Targeting
To determine whether the manufactured iPSC lines can be
differentiated into a neural lineage, we generated neural
stem cells (NSCs) from LiPSC-TR1.2 using a well-estab-
lished protocol (Swistowski et al., 2010). We observed no
difference in the timeline of NSC formation between
LiPSC-TR1.2 and XCL1 (XCell Science), a well character-
ized iPSC line reprogrammed by the identical method
(Shaltouki et al., 2015). Figure 5A, a–c, shows a homoge-
neous population of NSCs that uniformly expressed
SOX1 and NESTIN, markers of NSCs.
To demonstrate that the iPSC lines manufactured under
cGMP-compliant conditions can be genetically modified,
we tested one line, LiPSC-TR1.2, using a platformwe devel-
oped for the rapid generation of targeted clones in iPSCs via
TALEN and zinc finger nuclease (ZFN) (Pei et al., 2015). As a
proof of concept, we used a TALEN construct comprised of
a GFP reporter driven by the constitutively active CAG pro-
moter targeting the AAVS1 site. As expected, a similar tar-
geting efficiency was observed for LiPSC-TR1.2 and XCL1uthors
Figure 5. Validation of Neural Differentiation and Gene Targeting and Preparation of the Human iPSC MCB and WCBs
(A and B) Use of iPSCs (LiPSC-TR1.2) generated using a cGMP-compatible process in pre-clinical studies for neural differentiation (A) and
genetic engineering (B).
(A, a–c) Neural rosettes formed via EBs were isolated manually and expanded to a homogenous NSC population. Immunocytochemical
analysis showed positive expression of the NSC markers SOX1 and NESTIN. Scale bars, 200 mm, except in b and c (100 mm).
(B, a–c) TALEN-mediated homologous recombination targeting the safe harbor site AAVS1 on chromosome 19. A representative example of
a GFP-positive clone is shown. GFP was driven by the constitutively active CAG promoter. Scale bars, 200 mm.
(C) Human iPSCs generated under cGMP conditions can be used as MCB seed stocks to create working cell banks under both the GMP setting
(for manufacturing specialized cell therapy products) and in a non-GMP environment (to carry out research studies for multiple cell therapy
applications).(Pei et al., 2015). A representative image of a GFP-express-
ing clone is shown in Figure 5B, a–c.
Preparing a Seedstock and Matched Research-Grade
Stock
Upon completion of the cGMP manufacturing process, an
MCB of approximately 100 vials, with each vial containing
at least 2 3 106 human iPSCs, was produced. The cells
passed all established release criteria for iPSCs, standard
QC assays, and viral testing (listed in Table S3). The MCBs
are stored in vapor-phase liquid nitrogen in a warehouse
following established protocols and QA oversight. These
MCBs fulfill all criteria described by Stacey et al. (2013)
and the references therein, including manufacturing and
banking under standard GMP guidelines, traceability,Stem Cellhigh-quality (pertaining to robustness) and standard QC
testing, pluripotent stem cell characteristics, andwell docu-
mented storage. As illustrated in Figure 5C, iPSCMCBs can
be used for developing both GMP-compliant and research-
grade working cell banks (WCBs). The matched research-
gradeWCBs can be used by research laboratories to perform
pre-clinical studies (similar to the neural differentiation
and gene-targeting studies described earlier for LiPSC-
TR1.2) or to establish/optimize directed differentiation
protocols. These studies allow researchers to focus on
generating functional and clinically relevant cell types
such as dopaminergic neurons, retinal pigment epithelial
cells, or insulin-producing cells for cell transplantation
therapies. Indeed, we developed a research-grade WCB by
thawing one MCB vial and limited expansion to prepareReports j Vol. 5 j 647–659 j October 13, 2015 j ª2015 The Authors 655
about 50 cryopreserved vials, which were further tested for
karyotype stability. A WCB can be also generated under
GMPmanufacturing conditions to generate a clinical prod-
uct. Considering the limited number of MCB stocks, estab-
lishing these WCBs will allow the sustainable replenish-
ment of high-quality and valuable iPSCs generated under
cGMP manufacturing guidelines (Stacey et al., 2013; An-
drews et al., 2015).DISCUSSION
We have described a step-by-step cGMP-compliant process
to generate clinically compliant cell lines. The results of
bioassay/QC tests and manufacturing runs confirm that
the process is robust and reproducible. Moreover, the iPSCs
generated in each phase (i.e., process development,
training run, engineering run, and GMP manufacturing
run) fulfill pluripotent stem cell characteristics using stan-
dard assays from validated suppliers. Additionally, we
have shown that we can generate reporter sub-clones for
pre-clinical studies. Furthermore, these experiments
confirm that the lines produced in this manner can be
used for safe harbor gene editing to repair genetic defects
and that such engineered lines could be manufactured us-
ing a similar clinically compliant process.
Because iPSC could be used as starting material for multi-
ple products given the pluripotent nature of the cell line,
we felt that a larger seed stock andMCB should be planned.
In the HLA haplobank model that has been proposed
(Turner et al., 2013; Solomon et al., 2015), the same line
may be used for multiple individuals in addition to multi-
ple indications. We expect both proponents of autologous
and allogeneic iPSC-based therapy to utilize a seed stock
strategy. Specifically for autologous users, their back-up
cell stock can be preserved for future needs, whereas, for
allogeneic products, it can be used from a MCB.
From one of the GMPmanufacturing run clones, we pre-
pared a MCB and a research-grade WCB as well. Although
essentially identical, this research-grade WCB is signifi-
cantly less expensive (because the cGMP regulation is not
applied) and canbe used for evaluating the lines and the dif-
ferentiationprotocols thatmaybeused to generate a clinical
product. Lonza has filed a drug master file (DMF) with the
FDA that can be accessed via reference in a future investiga-
tional new drug (IND) submission. Although we used cord
blood (Raoet al., 2012), ourprocess is agnostic to the starting
material, and the episomal plasmid-based electroporation
protocol has been used successfully with a variety of tissue
samples in multiple laboratories (Chou et al., 2011 2015;
Okita et al., 2011; Goh et al., 2013; Schlaeger et al., 2015).
There were three levels of concerns we had to address
during the derivation process. One was related to the pro-656 Stem Cell Reports j Vol. 5 j 647–659 j October 13, 2015 j ª2015 The Acess of consent as discussed by Lowenthal et al., 2012.
Was the process of obtaining tissue compliant with the
new guidance provided by the FDA and compatible with
the final donor consent rule? Had we maintained the
appropriate level of confidentiality withHIPPA regulations,
and could we re-approach the donor should we need
further questions addressed? The second issue was keeping
a backup tissue sample and multiple clones of iPSC lines
from the same donor. In the end, we decided against this
for the first line we generated because this line will likely
be used for developing processes of differentiation and
for pre-clinical studies, but, for actual therapy, each group
will prefer generating its own lines. We expect, however,
that, if they opt to use the described process and SOPs,
then their cost will be significantly lower, and that the
FDA will accept much of the pre-clinical data that have
been generated with this line. The third issue was exposure
to serum and xeno material in the manufacturing process.
Our process, as described, does not include serum or
feeders, and all incoming raw materials were assessed for
their quality. Both primary and secondary suppliers were
evaluated. Our process, although xeno-free, is not animal
origin-free, but we have recently established a completely
animal origin-free process (data not shown). All materials
used in the process are commercially available, and, in
the future, the animal origin-free media will be made
commercially available as well. We note, however, that us-
ing xeno-free material is not an obligatory requirement in
the United States for use of a biologic material in a human.
Other, more routine issues were instrumentation valida-
tion, materials suppliers, and the development of release
assays. Although there is a recommendation from investi-
gators as to which additional tests should be considered,
several assays are required. In general, most tests need to
be validated, and the tests must be performed by a certified
vendor. Specific attention was given to the safety assays
and evaluation of pluripotent markers expression using
flow cytometry. As described earlier, plasmid clearance, kar-
yotype, mycoplasma, sterility, endotoxin level, and flow
cytometry assays were performed using a qualified or vali-
dated method or service provider. In addition to the
required tests, additional tests, such as embryoid body for-
mation, gene array analysis, comparative genomic hybrid-
ization + SNP microarray analysis, post-thaw evaluation
using alkaline phosphatase, and colony morphology,
were performed as optional tests or FIO, which is mainly
due to the subjective nature of these assays or the lack of
a qualified/validated service provider.
We worked with Dr. Zeng and colleagues to develop a
safe harbor reporter line using methods we have described
before. Our rationale here was two-fold: to obtain a re-
porter line that would not go silent after differentiation
and could be used for pre-clinical studies as an isogenicuthors
labeled control and to demonstrate that gene targeting is
possible and can be implemented at the seed bank stage
(i.e., downstream of the derivation and expansion pro-
cess). We expect that this will make getting approval of
an engineered sub-clone as a product much easier in the
future.
We note that several alternate paths could be followed to
obtain a clinically compliant line (Malik and Rao 2013;
Schlaeger et al., 2015). Because these processes will use
different starting materials, different reagents, and, pre-
sumably, a different site of manufacture, each of those
groups will have to develop their own 510k or DMF pack-
age as part of the IND application. Investigators could
choose to access our process in its entirety and reference
our DMF. Alternatively, they could modify our process,
which would significantly reduce their development
time. Our time range to develop a process for manu-
facturing iPSC MCBs under GMP and performing the
manufacturing runs was more than 2 years.
Although we followed all of the rules, we hesitate to use
the phrase cGMP-compliant because this is a determina-
tion that will ultimately be made by the regulatory au-
thorities when the entire IND package is provided to the
FDA. We also note that the approval of the use of this
line as part of an IND process does not presume that
this will be deemed cGMP-compatible in other regulatory
domains such as Europe, Japan, or China. We will take the
DMF that we have prepared to these other authorities to
develop a gap analysis. We are aware that Europe has a
well-defined consultation process for this purpose
(Ancans, 2012).
Our goal in making a matched research-grade iPSC line
from the cells generated through manufacturing runs was
to make a standardized line available that could be used
to evaluate the directed differentiation process. We under-
stand that use of this line by different organizations may
still require incorporating a new risk assessment and valida-
tion to address the local reagents and conditions. However,
this scenario will determine whether the processes will
work or need to be standardized further. If it works with
the matched research sample, then it will work with the
cGMP-manufactured seed stock and, perhaps, with the
lines made using the same process. If there was variability,
then wewould know by comparing the results between the
matched research-grade line and linesmade during the pro-
cess development phase.We believe that this will result in a
significant time and cost reduction and, perhaps evenmore
importantly, a reduction in risk as individual investigators
move their projects forward.
In summary, we believe that this is a complete report of a
process for the sourcing, derivation, and development of a
clinically compliant iPSC MCB that is widely available for
use and evaluation. Additional lines can be generated usingStem Cellthis reproducible process, and the process can be readily
adapted to meet the European and Japanese guidelines.EXPERIMENTAL PROCEDURES
Generation of Human Induced Pluripotent Stem Cells
Cryopreserved human umbilical cord blood (hUCB) CD34+ cells
(Lonza, 2C-101) were thawed and expanded in a priming medium
described in the Supplemental Experimental Procedures. 1 3 106
hUCB CD34+ cells were reprogramed using episomal plasmids en-
codingOct4, Sox2, Klf4, c-Myc, and Lin28 and pEB-Tg (Chen et al.,
2011; Dowey et al., 2012) using the 4D nucleofector system and P3
solution kit (Lonza, V4XP-3012). Details regarding isolation and
expansion of iPSC colonies are provided in the Supplemental
Experimental Procedures.Characterization of Human Induced Pluripotent
Stem Cells
Human iPSCs were characterized using in-process and final charac-
terization methods, including flow cytometry and immunocyto-
chemistry techniques evaluating the expression of pluripotent
stem cells markers, karyotype, and STR analyses, embryoid body
formation, whole genome expression, qPCR for the detection of re-
sidual plasmids, and standard safety assays, as described in the Sup-
plemental Experimental Procedures.
Detailed procedures are provided in the Supplemental Experi-
mental Procedures and are available upon request or by accessing
the DMF.
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